Tech Company Financing Transactions
Fusion Pharmaceuticals Funding Round
Fusion Pharmaceuticals, based in Boston, secured $25 million from Johnson & Johnson Development Corporation, Genesys Capital and Healthcap Venture Capital.
Transaction Overview
Company Name
Announced On
2/24/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Johnson & Johnson Development Corporation (Lead Investor) (Asish Xavier)
Proceeds Purpose
Fusion Pharmaceuticals will use the financing proceeds to advance its lead program, FPX-01, into human clinical trials.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
451 D St. 930
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
Fusion Pharmaceuticals is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Valliant
Chief Financial Officer
John Crowley
Chief Scientific Officer
Eric Burak
VP - Bus. Development
Marc Schwabish
VP - Finance
Lynn Wick
Browse more venture capital transactions:
Prev: 2/24/2017: Shinezone venture capital transaction
Next: 2/24/2017: Mercatus venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs